Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin effect on glucagon response in T2DM
NCT00390520Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin Sequence with Placebo Sequence (2 arms). Primary endpoint: Glucagon counterregulatory response to hypoglycemia at 4 weeks. Started Sep 2006; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00390520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390520.